Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S.
Corti F, et al. Among authors: de braud f.
BMC Cancer. 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2.
BMC Cancer. 2023.
PMID: 37752423
Free PMC article.